New York, September 24, 2024 - PRISM MarketView - Today the clinical stage biopharmaceutical company Lipella Pharmaceuticals (LIPO) reported encouraging tolerability results in its Phase 2a trial for its Oral Lichen Planus (OLP) treatment, LP-310. Three participants have completed the four-week treatment with LP-310, an oral rinse and have reported the treatment was well tolerated with no unpleasant taste.
LP-310 is derived from Lipella’s lead candidate, LP-10 which had been originally developed to target hemorrhagic cystitis. LP-310 is a proprietary liposomal-tacrolimus formulation that targets underlying causes of OLP in an effort to provide a more effective alternative to the current treatment options. Currently, there are no FDA-approved pharmacotherapies for Oral Lichen Planus, and LP-310 is the only topical treatment in development for OLP.
“Oral Lichen Planus is a highly disruptive condition that significantly impacts patients’ daily lives. Given the severity of symptoms, tolerability is critical. Symptomatic side effects from current treatments often lead to frequent dose interruptions or delays, which can further complicate disease management. The fact that LP-310 has been well tolerated so far, without unpleasant taste, is very encouraging. We look forward to gathering more data on the safety side as we continue this pivotal trial.”
Dr. Michael Chancellor, Chief Medical Officer of Lipella Pharmaceuticals
About Lipella Pharmaceuticals
Lipella is a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Additionally, Lipella maintains a therapeutic focus on diseases with significant, unaddressed morbidity and mortality where no approved drug therapy currently exists. Lipella completed its initial public offering in December 2022. For more information, please visit www.lipella.com or LinkedIn.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities